## HCA: HCA Healthcare, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.6% below STRENGTH zone (3.0-6.0%); PEG 1.22 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($465.68)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 8, Bearish: 0)

**1. Amundi Boosts Holdings in HCA Healthcare, Inc. $HCA**
- Source: MarketBeat | 20251208T130804 | Bullish | Relevance: 99%
-  Amundi significantly increased its stake in HCA Healthcare by 36.2% in Q2, bringing its total holdings to 394,665 shares valued at $149.2 million. This comes as HCA Healthcare reported strong Q3 earnings, surpassing expectations with an EPS of $6.96 and revenue of $19.16 billion, leading to several analyst price target increases and a "Moderate Buy" consensus rating. Despite an insider sale by EVP Michael R. McAlevey, institutional investors collectively own a substantial 62.7% of the company, and the company announced a quarterly dividend of $0.72 per share.

**2. HCA Healthcare (NYSE: HCA) appoints Virginia Tenpenny to lead community engagement**
- Source: Stock Titan | 20251209T133231 | Bullish | Relevance: 99%
- HCA Healthcare has appointed Virginia Tenpenny as its new Vice President of Community Engagement, effective January 12, 2026. Tenpenny, who has over two decades of experience in corporate community impact, will lead the company's community engagement strategy, succeeding the retiring Joanne Pulles. This role oversees social and charitable investments, colleague giving, community outreach, and strategic partnerships.

**3. HCA Healthcare Names Virginia Tenpenny Vice President of Community Engagement**
- Source: Business Wire | 20251209T130813 | Bullish | Relevance: 99%
-  HCA Healthcare, Inc. announced Virginia Tenpenny as its new Vice President of Community Engagement, effective January 12, 2026. Tenpenny will lead strategies for social and charitable investments, colleague giving, community outreach, and strategic partnerships, bringing over two decades of corporate community impact experience. She succeeds Joanne Pulles, who is retiring after 26 years with HCA Healthcare, during which she established the HCA Healthcare Hope Fund.

**4. Artificial Intelligence at HCA Healthcare – Two Use Cases**
- Source: Emerj Artificial Intelligence Research | 20251208T111621 | Bullish | Relevance: 98%
-  HCA Healthcare is leveraging AI in two key areas. First, they partnered with Google Cloud and Commure to implement generative AI for clinical documentation, aiming to improve workflow efficiency and free up clinicians' time. Second, they collaborated with GE HealthCare to develop CareIntellect for Perinatal, a cloud-based platform utilizing AI and predictive analytics to centralize maternal and fetal data, detect risks earlier, and strengthen perinatal outcomes.

**5. HCA taps new VP of community engagement**
- Source: Healthcare Dive | 20251209T154515 | Bullish | Relevance: 98%
-  HCA Healthcare has appointed Virginia Tenpenny as its new vice president of community engagement, overseeing charitable investments, outreach, and strategic partnerships. Tenpenny will join HCA on January 12, replacing Joanne Pulles, who is retiring after 26 years. In her new role, Tenpenny will build on HCA's significant community contributions, which exceeded $48.5 million in enterprise giving and over $18 million from employee matching funds in 2024.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-13 | Wells Fargo | $431 | $412 | +5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-13 | Wells Fargo | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($3.12M) |
| Sells | 4 ($14.79M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 29.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 7 |

**Top Holders:**
- Vanguard Group Inc: 6.5% (-3.8%)
- Blackrock Inc.: 5.5% (-3.7%)
- Sanders Capital, LLC: 4.7% (-3.9%)
- State Street Corpora: 3.3% (-5.9%)
- JPMORGAN CHASE & CO: 2.6% (+82.2%)

### Key Risks

1. Heavy insider selling: $15M sold (4 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.22 suggests fair value with growth premium. Forward P/E 16.4x stretched relative to 8% growth. Quality metrics strong (ROE 136%, ROA 12%). Balance sheet: $3.1B free cash flow. Insider selling cluster ($14.8M in 90 days), potential headwind. Institutional flow bullish (2 buying vs 7 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $114.3B |
| Beta | 1.37 |
| 52W Range | $289.98 - $520.00 |
| Short Interest | 2.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.22 |
| Forward P/E | 16.4 |
| Current P/E | 17.7 |
| YoY Growth | 7.7% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -4.3% to -2.6% (+1.7% in 5 days), confirming momentum buildup. Below STRENGTH zone by 5.6pp (needs >3.0% for momentum thesis). MRS_5 turning positive (0.1%) - potential reversal signal. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-3.20), momentum weakening. RSI neutral at 56.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.62% (CS: 29) | Weak |
| RSI_14 | 55.6 | Neutral |
| MACD Histogram | -3.20 | Bearish |
| vs SMA20 | 1.001x | Above |
| vs SMA50 | 1.060x | Above |
| vs SMA200 | 1.254x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $488.50
- **Stop Loss:** $465.68 (4.7% risk)
- **Target:** $511.32 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 13
- **Position Value:** $6,350.50
- **Portfolio %:** 6.35%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not inverted—indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-01-23 (Est: $7.46)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.73 | $6.96 | +21.6% |
| 2025Q2 | $6.32 | $6.84 | +8.2% |
| 2025Q1 | $5.75 | $6.45 | +12.1% |
| 2024Q4 | $6.14 | $6.22 | +1.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*